Monopar Therapeutics (MNPR) Common Equity (2016 - 2026)
Monopar Therapeutics (MNPR) posted Common Equity of $137.8 million for Q4 2025, down 2.64% sequentially from $141.6 million in Q3 2025, and up 150.43% YoY from $55.0 million in Q4 2024.
Monopar Therapeutics (MNPR) Common Equity (2016 - 2026) Analysis & Trends
Monopar Therapeutics has reported Common Equity for 10 years, with the latest figure at $137.8 million in Q4 2025.
- Quarterly Common Equity rose 150.43% year-over-year to $137.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $137.8 million (up 150.43% YoY) and the FY2025 annual result came in at $137.8 million, up 150.43% from the prior year.
- Common Equity eased to $137.8 million in Q4 2025 per MNPR's latest filing, from $141.6 million in the prior quarter.
- Over five years, Common Equity peaked at $141.6 million in Q3 2025 and troughed at $4.9 million in Q3 2024.
- A 5-year average of $31.5 million and a median of $15.7 million in 2022 frame the typical range for Common Equity.
- The sharpest annual moves came in 2023 and 2025: Common Equity plunged 47.28% in 2023, then surged 2761.61% in 2025.
- Over 5 years, Common Equity stood at $18.9 million in 2021, then sank by 46.73% to $10.1 million in 2022, then sank by 44.62% to $5.6 million in 2023, then jumped by 884.95% to $55.0 million in 2024, then jumped by 150.43% to $137.8 million in 2025.
- According to Business Quant data, Common Equity over the past three periods registered $137.8 million, $141.6 million, and $52.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Monopar Therapeutics | 965.64 Mn | 912.88 Mn | - | 130.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 130.85 Mn |
| Dec 31, 2025 | 137.83 Mn |
| Sep 30, 2025 | 141.56 Mn |
| Jun 30, 2025 | 52.20 Mn |
| Mar 31, 2025 | 53.59 Mn |
| Dec 31, 2024 | 55.04 Mn |
| Sep 30, 2024 | 4.95 Mn |
| Jun 30, 2024 | 6.09 Mn |
| Mar 31, 2024 | 7.48 Mn |
| Dec 31, 2023 | 5.59 Mn |
| Sep 30, 2023 | 6.61 Mn |
| Jun 30, 2023 | 7.84 Mn |
| Mar 31, 2023 | 8.94 Mn |
| Dec 31, 2022 | 10.09 Mn |
| Sep 30, 2022 | 12.51 Mn |
| Jun 30, 2022 | 14.52 Mn |
| Mar 31, 2022 | 16.97 Mn |
| Dec 31, 2021 | 18.94 Mn |
| Sep 30, 2021 | 21.28 Mn |
| Jun 30, 2021 | 23.35 Mn |